Also known as: Transplant medications
Immunosuppressants prevent organ rejection after transplant and control autoimmune conditions like lupus, inflammatory bowel disease, and rheumatoid arthritis. Pharmacogenetics is unusually critical in this class because the drugs have narrow therapeutic windows: too little and the immune system rejects the graft (or reactivates autoimmune disease), too much and infection or kidney damage follow. TPMT and NUDT15 guide azathioprine dosing; CYP3A5 guides tacrolimus.
Each link goes to the drug's full pharmacogenetics page with CPIC and FDA phenotype recommendations.
Combined products and brand names for the medications above. Each links to a pharmacogenetic breakdown.
This page covers the pharmacogenetics of immunosuppressants in general. A Gene2Rx report tells you how your personal genotype interacts with every drug on this page.
Get your report Look up a medicationInformational only, not medical advice. Pharmacogenetic guidelines describe population-level patterns that inform prescribing decisions. Never start, stop, or change a medication without talking to your prescribing clinician.